Bioventus (BVS) Invested Capital (2020 - 2026)

Bioventus (BVS) has reported Invested Capital for 7 consecutive years, with $525.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital fell 3.07% year-over-year to $525.9 million; the trailing twelve-month figure through Jun 2026 stood at $525.9 million (down 3.07% YoY), and the FY2025 full-year result was $522.4 million, changed 0.22% from the prior year.
• Invested Capital advanced to $525.9 million in Q2 2026 per BVS's latest filing, from $506.3 million in the prior quarter.
• Across five years, Invested Capital topped out at $966.1 million in Q3 2022 and bottomed at $506.3 million in Q1 2026.
• Historically, Invested Capital has averaged $644.8 million across 5 years, with a median of $590.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Invested Capital soared 141.24% in 2022, then slumped 35.9% in 2023.
• Over 5 years, Invested Capital stood at $830.3 million in 2022, then slipped by 25.81% to $616.0 million in 2023, then decreased by 15.38% to $521.2 million in 2024, then advanced by 0.22% to $522.4 million in 2025, then gained by 0.66% to $525.9 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $525.9 million, $506.3 million, and $522.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.